AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.
Overview
Choosing between AbbVie (NYSE:ABBV) and Novo Nordisk (NYSE:NVO) requires balancing a diversified income play against a focused growth leader in the massive metabolic health market during 2026.
AbbVie has historically relied on blockbuster drugs while aggressively acquiring new pipelines to maintain its market share. Meanwhile, Novo Nordisk has seen a surge in demand for its GLP-1 therapies, positioning itself as a dominant force in chronic disease management across the globe.
Details
AbbVie operates as a diversified biopharmaceutical company that targets complex conditions in immunology, oncology, and neuroscience. Its primary customers include wholesale distributors, hospitals, and pharmacy benefit managers who facilitate the delivery of high-cost specialty drugs. In the United States, three wholesale distributors, McKesson Corp (NYSE:MCK), Cardinal Health (NYSE:CAH), and Cencora (NYSE:COR), account for nearly all pharmaceutical product sales. Customer concentration like this adds a layer of risk to the business, as the company relies heavily on these specific channels for its revenue.
Source
Originally published at www.fool.com.